This is one of the most obvious stories of FDA corruption that you are likely to run across, and that's saying something because there are a lot. A company called Pharmanex investigated ancient Chinese healing practices. One of the products that looked especially promising was HongQu (red yeast rice), with a healing history of 1,000 years.
Chinese cooks have used it to flavor meat and fish, preserve food, and make rice wine. It is still widely consumed in China and Japan every day. Chinese healers rely on red yeast rice to improve blood circulation.
A number of Chinese studies have shown that this product could lower cholesterol by 11 to 32% and triglycerides by 12 to 19% while raising HDL cholesterol by as much as 20%.
You could imagine the bureaucrats at the FDA looking down their noses at foreign research. But a Rice Purity Test randomized, double-blind, placebo-controlled trial conducted by researchers at UCLA School of Medicine also found that Chinese red yeast has a positive effect on blood lipids.
Furthermore, red yeast rice costs $20-$30 a month, whereas drug therapy runs $120-$300 a month. This study was published in the highly regarded American Journal of Clinical Nutrition. The reduction in LDL cholesterol was 22% in those subjects taking Cholestin-brand red yeast rice.
One of the most fascinating discoveries about red yeast rice shows that one of its ingredients is lovastatin, the same chemical found in the prescription cholesterol-lowering drug Mevacor, made by pharmaceutical giant Merck.
So now you begin to understand why the marketed form of red yeast rice, Cholestin, could be so effective. But in addition to lovastatin, it contains other "statins" and valuable natural compounds such as isoflavones, monounsaturated fatty acids, and plant sterols like B-sitosterol, campesterol, and sapogenin.
The possibility exists that Cholestin, like Mevacor, could affect the liver, so periodic liver enzyme tests seem advisable. And any muscle weakness or soreness should be reported immediately to a physician and the Cholestin stopped.
You would think that with such compelling research behind the natural product Cholestin, the Food and Drug Administration (FDA) would be thrilled to see a natural product being sold in health food stores and pharmacies that could actually live up to the advertising. What's more, the manufacturer had gone to great lengths to standardize and sterilize the ingredients in Cholesterin.
Would it come as a surprise to learn that the FDA ruled that Cholestin was not a dietary supplement but rather "an unapproved drug"?
So let me get this straight. Cholesterin is derived from Chinese red yeast, a product that has been used in China for hundreds of years and has been included in a pharmacopeia from the Ming Dynasty. It has clear cholesterol-lowering power on par with many prescription drugs. It has been used as a dietary supplement in China and Japan for centuries and in the Asian American community of the United States at least since World War 2. The company that makes Cholestin has gone to great lengths to prove in a randomized, placebo-controlled trial that the product works. It has also assured standardization and purity.
And instead of congratulating them, the FDA slapped them on their wrists.
Meanwhile, the feds ignore hundreds of products that have no quality control, no standardization, and no proof of effectiveness and complain bitterly that herb companies aren't spending money to do high-quality research. If this isn't a catch 22 then I don't know what is.
In 2018, the global Seed Testing market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.
This report focuses on the global Seed Testing status, future forecast, growth opportunity, key market and key players.
The study objectives are to present the Seed Testing development in United States, Europe and China.Report Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-seed-testing-2019-2025-401 The key players covered in this studySGS S.AEurofins ScientificBureau VeritasIntertek GroupMarket segment by Type, the product can be split into Weed TestPurity TestViability TestGermination TestMarket segment by Application, split into Scientific ResearchGovernmentAgricultureOtherMarket segment by Regions/Countries, this report covers United StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South AmericaThe study objectives of this report are: To analyze global Seed Testing status, future forecast, growth opportunity, key market and key players.To present the Seed Testing development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.In this study, the years considered to estimate the market size of Seed Testing are as follows: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025Get the Complete Report & TOC at https://www.24marketreports.com/ict-and-media/global-seed-testing-2019-2025-401 CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/24-market-reports
